In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported

Blood Adv. 2021 Dec 14;5(23):5057-5059. doi: 10.1182/bloodadvances.2021004983.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Cohort Studies
  • Humans
  • Mutation*
  • Prevalence
  • Sarcoma, Myeloid / diagnosis
  • Sarcoma, Myeloid / epidemiology
  • Sarcoma, Myeloid / genetics*